Buserelin is a well-studied peptide compound, and readers often want to know how much clinical research actually backs its use. Public trial registries offer a window into that question, even when detailed label information is not part of this summary.
Key takeaways
- Buserelin has 43 registered clinical trials in public databases.
- Trials include work in ovarian stimulation protocols and in prostate cancer treatment combinations.
- One sampled trial, a Phase 3 dual ovarian stimulation study, is listed as completed.
- Another sampled trial, a Phase 1 study combining buserelin with bicalutamide, was terminated.
- Buserelin has a PubChem CID of 50225, reflecting its established chemical identity.
What buserelin is
Buserelin is a synthetic peptide made up of a chain of amino acids, with a molecular formula of C60H86N16O13. It is recognized within research and clinical literature as a compound related to gonadotropin-releasing hormone (GnRH) analogs, based on its inclusion in trials involving LH-RH agonist regimens and ovarian stimulation.
What the evidence shows
Public registries list 43 clinical trials involving buserelin. Among the sampled studies, a Phase 3 trial comparing dual ovarian stimulation and Shanghai protocols in poor ovarian responders reached completed status. A Phase 1 dose-finding study pairing buserelin with an investigational agent and bicalutamide in men with metastatic prostate cancer was terminated. A separate Phase 3 trial examining ovarian stimulation based on genotype status is listed as suspended, illustrating that trial outcomes in this space vary.